1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 130,00 | 135,00 | 20:23 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.03. | Belite Bio: Positive Phase-3-Studiendaten für Tinlarebant bei Morbus Stargardt | 1 | Investing.com Deutsch | ||
| 04.03. | Mizuho reiterates Belite Bio stock rating on NDA timeline update | 1 | Investing.com | ||
| 04.03. | H.C. Wainwright raises Belite Bio stock price target on NDA timeline | 2 | Investing.com | ||
| 03.03. | Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook | 3 | Investing.com | ||
| 03.03. | Belite Bio targets Q2 2026 NDA submission and $200M-$250M commercialization spend for Stargardt therapy while cash reserves surge | 2 | Seeking Alpha | ||
| 02.03. | Belite Bio Non-GAAP EPS of -$0.19 beats by $0.38 | 2 | Seeking Alpha | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 02.03. | Belite Bio, Inc: Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | 366 | GlobeNewswire (Europe) | Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application... ► Artikel lesen | |
| 27.02. | Exploring Belite Bio's Earnings Expectations | 1 | Benzinga.com | ||
| 30.01. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.01. | H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target | 2 | Investing.com | ||
| 27.01. | Belite Bio completes enrollment in phase 2/3 STGD1 drug trial | 2 | Investing.com | ||
| 27.01. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.01. | BofA Securities initiates coverage on Belite Bio stock with Buy rating | 4 | Investing.com | ||
| 16.01. | Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock | 1 | Investing.com | ||
| 06.01. | Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target | 2 | Investing.com | ||
| 03.12.25 | Belite Bio stock price target raised to $187 from $132 at Benchmark | 3 | Investing.com | ||
| 02.12.25 | Mizuho upgrades Belite Bio stock to Outperform on positive trial data | 1 | Investing.com | ||
| 02.12.25 | Mizuho stuft Belite Bio nach positiven Studiendaten auf 'Outperform' hoch | 10 | Investing.com Deutsch | ||
| 02.12.25 | Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering | 2 | Seeking Alpha | ||
| 02.12.25 | Belite Bio prices public offering of ADSs at $154 each | 1 | Investing.com |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,304 | -1,62 % | TKMS Aktie: Sturz oder Allzeithoch - Evotec, Exasol, Formycon, Kontron und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 21,000 | 0,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| OCUGEN | 1,615 | -4,95 % | Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (pPotential 2X treatment benefit compared to 15% and 22% reductions... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,290 | -3,14 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,210 | -4,98 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,041 | +0,79 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| ABIVAX | 90,20 | -4,85 % | Abivax-Aktie: Übernahmephantasie verflogen? | Das französische Biotechunternehmen Abivax hat mit der Veröffentlichung seiner Geschäftszahlen für 2025 und einem aktuellen Unternehmensupdate die Aufmerksamkeit der Märkte wieder stärker auf operative... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,170 | -4,17 % | SRPT Stock Surges on Promising Early Results From siRNA Programs | ||
| GERON | 1,269 | -4,80 % | Geron beruft Patricia S. Andrews und Constantine Chinoporos in den Verwaltungsrat | ||
| BASILEA | 56,50 | -1,40 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea startet erste klinische Studie am Menschen für neuartiges Antibiotikum BAL2420 | Allschwil, 23. März 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| GALAPAGOS NV | 26,060 | -1,29 % | Galapagos NV: Galapagos Announces Nomination of Gino Santini to its Board of Directors | Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine
Mr. Santini will bring extensive corporate governance, business development... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,810 | -4,10 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates | On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,032 | +3,72 % | IBA SA: Telix selects IBA Cyclone KIUBE to support manufacturing expansion in the U.S. | Louvain-la-Neuve, Belgium- March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical... ► Artikel lesen | |
| REPLIGEN | 99,32 | +0,06 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| ARGENX | 612,00 | +1,09 % | $100 Invested In argenx 5 Years Ago Would Be Worth This Much Today |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 129,00 Euro und damit +0,78 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.